Filtered By:
Specialty: Drugs & Pharmacology
Cancer: Cancer
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 1000 results found since Jan 2013.
VPS34-IN1 induces apoptosis of ER + breast cancer cells via activating PERK/ATF4/CHOP pathway
Biochem Pharmacol. 2023 Jun 6:115634. doi: 10.1016/j.bcp.2023.115634. Online ahead of print.ABSTRACTVPS34-IN1 is a specific selective inhibitor of Class III Phosphatidylinositol 3-kinase (PI3K) and has been shown to exhibit a significant antitumor effect in leukemia and liver cancer. In current study, we focused on the anticancer effect and potential mechanism of VPS34-IN1 in estrogen receptor positive (ER + ) breast cancer. Our results revealed that VPS34-IN1 inhibited the viability of ER + breast cancer cells in vitro and in vivo. Flow cytometry and western blot analyses showed that VPS34-IN1 treatment induced breast can...
Source: Biochemical Pharmacology - June 8, 2023 Category: Drugs & Pharmacology Authors: Qiuya Wu Duanfang Zhou Zhengze Shen Bo Chen Gang Wang Lihong Wu Limei Zhang Xiaoli Li Lie Yuan Yuanli Wu Na Qu Weiying Zhou Source Type: research
Targeted and Functional Genomics Approaches to the Mechanism of Action of Lagunamide D, a Mitochondrial Cytotoxin from Marine Cyanobacteria
Biochem Pharmacol. 2023 May 16:115608. doi: 10.1016/j.bcp.2023.115608. Online ahead of print.ABSTRACTLagunamide D, a cyanobacterial cyclodepsipeptide, exhibits potent antiproliferative activity against HCT116 colorectal cancer cells (IC50 5.1 nM), used as a model system to probe the mechanism of action. Measurements of metabolic activity, mitochondrial membrane potential, caspase 3/7 activity and cell viability indicate the rapid action of lagunamide D on mitochondrial function and downstream cytotoxic effects in HCT116 cells. Lagunamide D preferentially targets the G1 cell cycle population and arrests cells in G2/M phase ...
Source: Biochemical Pharmacology - May 18, 2023 Category: Drugs & Pharmacology Authors: Danmeng Luo Ranjala Ratnayake Kalina R Atanasova Valerie J Paul Hendrik Luesch Source Type: research
Nanocarriers for Sirna Delivery Aimed at the Treatment of Melanoma: Systematic Review
CONCLUSION: Such being the case, the development of these systems becomes a non-invasive and promising option for the treatment of melanoma.PMID:37170995 | DOI:10.2174/1567201820666230425234700
Source: Current Drug Delivery - May 12, 2023 Category: Drugs & Pharmacology Authors: Brenda Regina de Araujo Tatielle do Nascimento Ana Paula Dos Santos Matos Vanessa Brand ão de Souza Belmiro Mariana Sato de Souza de Bustamante Monteiro Ralph Santos-Oliveira Eduardo Ricci-Junior Source Type: research
Quassinoid analogs exert potent antitumor activity via reversible protein biosynthesis inhibition in human colorectal cancer
Biochem Pharmacol. 2023 Apr 26:115564. doi: 10.1016/j.bcp.2023.115564. Online ahead of print.ABSTRACTCellular protein synthesis is accelerated in human colorectal cancer (CRC), and high expression of protein synthesis regulators in CRC patients is associated with poor prognosis. Thus, inhibition of protein synthesis may be an effective therapeutic strategy for CRC. We previously demonstrated that the quassinoid bruceantinol (BOL) had antitumor activity against CRC. Herein, potent tumor growth suppression (>80%) and STAT3 inhibition was observed in two different mouse models following BOL administration. Loss of body and...
Source: Biochemical Pharmacology - April 28, 2023 Category: Drugs & Pharmacology Authors: Ning Wei James Burnett Desirae L Crocker Yixian Huang Song Li Peter Wipf Edward Chu John C Schmitz Source Type: research
Short interfering RNA in colorectal cancer: is it wise to shoot the messenger?
This study focuses on many innovative siRNA therapies and methodologies for delivering siRNA therapeutics to the malignant site safely and effectively for the treatment of CRC. Treatment of CRC using siRNA-associated nanoparticles (NPs) may inhibit the activity of oncogenes and MDR-related genes by targeting a range of signaling mechanisms. This study summarizes several siRNAs targeting signaling molecules, as well as the therapeutic approaches that might be employed to treat CRC in the future.PMID:37011722 | DOI:10.1016/j.ejphar.2023.175699
Source: European Journal of Pharmacology - April 3, 2023 Category: Drugs & Pharmacology Authors: Kiruthiga Chandramohan Devasahayam Jaya Balan Kasi Pandima Devi Seyed Fazel Nabavi Sara Reshadat Maryam Khayatkashani Sepideh Mahmoodifar Rosanna Filosa Nilofar Amirkhalili Soroush Pishvaei Omolbanin Sargazi Aval Seyed Mohammad Nabavi Source Type: research
Cationic lipid-assisted nanoparticles for simultaneous delivery of CD47 siRNA and R848 to promote antitumor immune responses
Discussion: To our best knowledge, our study pioneered co-delivery system for hydrophilic siCD47 and hydrophobic R848. It can maximize break tumor immune escape caused by CD47 and simultaneously enhance antigen presentation by activating DCs for effector T cell killing while regulating the tumor microenvironment as expected. Not only does it conform to the reports of previous basic research, but also it can break the bottleneck of their clinical application hopefully. Collectively, our findings could lay the foundation for future therapeutic strategies of TNBC.
Source: Frontiers in Pharmacology - March 31, 2023 Category: Drugs & Pharmacology Source Type: research
Targeting ZDHHC9 potentiates anti-programmed death-ligand 1 immunotherapy of pancreatic cancer by modifying the tumor microenvironment
Biomed Pharmacother. 2023 Mar 22;161:114567. doi: 10.1016/j.biopha.2023.114567. Online ahead of print.ABSTRACTImmune checkpoint blockade (ICB) therapy targeting the programmed death 1/programmed death-ligand 1 (PD-1/PD-L1) axis has achieved considerable success in treating a wide range of cancers. However, most patients with pancreatic cancer remain resistant to ICB. Moreover, there is a lack of optimal biomarkers for the prediction of response to this therapy. Palmitoylation is mediated by a family of 23 S-acyltransferases, termed zinc finger Asp-His-His-Cys-type palmitoyltransferases (ZDHHC), which precisely control vari...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - March 24, 2023 Category: Drugs & Pharmacology Authors: Zhiqing Lin Keke Huang Hui Guo Manli Jia Qiuqin Sun Xuhao Chen Jianmin Wu Qingqing Yao Peng Zhang Sergii Vakal Zhengzhi Zou Haiyao Gao Lei Ci Jiangfan Chen Wei Guo Source Type: research
Nanoparticles overcome adaptive immune resistance and enhance immunotherapy via targeting tumor microenvironment in lung cancer
Lung cancer is one of the common malignant cancers worldwide. Immune checkpoint inhibitor (ICI) therapy has improved survival of lung cancer patients. However, ICI therapy leads to adaptive immune resistance and displays resistance to PD-1/PD-L1 blockade in lung cancer, leading to less immune response of lung cancer patients. Tumor microenvironment (TME) is an integral tumor microenvironment, which is involved in immunotherapy resistance. Nanomedicine has been used to enhance the immunotherapy in lung cancer. In this review article, we described the association between TME and immunotherapy in lung cancer. We also highligh...
Source: Frontiers in Pharmacology - March 24, 2023 Category: Drugs & Pharmacology Source Type: research
